<html xml:lang="en-us" lang="en-us" xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops"><head>
    <link rel="stylesheet" type="text/css" href="../../../../css/base.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/kotobeeInteractive.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/base.css" />
<link rel="stylesheet" type="text/css" href="../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/kotobeeInteractive.css" />

    <script type="text/javascript" src="../../../../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../../../../js/global.js"></script>
<script type="text/javascript" src="../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../js/global.js"></script>

    <title>Lignocaine infusions</title>
    

<meta name="m-checksum" content="-18238669" />
<meta charset="utf-8" />
 <meta name="kotobee-chapter" content="epubypzqs\EPUB\xhtml\sqchdf.xhtml" />
<meta name="kotobee-book" content="urn:uuid:d75d8b48-c76b-9ec4-4518-c91ddbf1e03c" />
</head>
<body>
<p><strong><em>Lidocaine (previously lignocaine) in palliative patients should only be used under the direction of a palliative care specialist. Speak to one before initiating lidocaine.</em></strong></p>

<p>A subcutaneous infusion of lidocaine <em><sup>(non-PBS)</sup></em> is a useful treatment option in patients with a terminal illness who have severe pain refractory to other treatments. It requires careful assessment, consent and monitoring by a clinician familiar with its place, use and evidence-base relative to alternatives.<br />
<br />
<strong>Indication: </strong>Pain (especially neuropathic pain) refractory to other analgesia.</p>

<p><strong>Before starting</strong></p>

<ul>
	<li>Exclude contraindications by performing an ECG. Do not use in patients with a history of an arrhythmia without first discussing with a cardiologist</li>
	<li>Exhaust all other available treatment options before using in patients in the “precautions” group</li>
	<li>Check the blood pressure, heart rate, respiratory rate and sedation and pain scores</li>
	<li>Communicate and gain consent</li>
</ul>

<p><strong>Commencing an infusion</strong></p>

<ul>
	<li>Start at a dose of 500mg via continuous subcutaneous infusion over 24 hours. In a thin and elderly person, consider beginning at 250 mg over 24 hours</li>
	<li>Monitor HR, RR, BP and sedation score at 2, 4 and 8 hours and thereafter three times daily</li>
	<li>Perform an ECG the day following infusion</li>
</ul>

<p><strong>Increasing the dose</strong></p>

<ul>
	<li>If inadequate analgesia is achieved, consider increasing the infusion rate by 250-500mg every 24-48 hours to a maximum dose of 1,500mg per day</li>
	<li>With each increase in dose, recheck the ECG within 24 hours</li>
</ul>

<p><strong>Stopping an infusion</strong></p>

<ul>
	<li>If bradycardia, hypotension, a cardiac arrhythmia or any other significant adverse effects occur, cease the infusion</li>
	<li>If&#160;there has been no improvement in pain 24-hours after reaching the maximum dose, cease the infusion</li>
	<li>If good analgesia occurs, consider gradually tapering the infusion by reducing in 250-500 mg increments every 24-48 hours</li>
	<li>Consider complementing the reduction in lignocaine with a corresponding increase in other analgesic agents, e.g. methadone, or converting to mexiletine</li>
</ul>

<table>
	<tbody>
		<tr>
			<td><strong>Absolute Contraindications</strong></td>
		</tr>
		<tr>
			<td>AV block</td>
		</tr>
		<tr>
			<td>Stokes-Adams attacks</td>
		</tr>
		<tr>
			<td>Wolf-Parkinson-White syndrome</td>
		</tr>
		<tr>
			<td>Previous sensitivity</td>
		</tr>
		<tr>
			<td>
			<p><strong>Precautions</strong></p>
			</td>
		</tr>
		<tr>
			<td>Arrhythmias</td>
		</tr>
		<tr>
			<td>Cardiac failure</td>
		</tr>
		<tr>
			<td>Seizures</td>
		</tr>
		<tr>
			<td>Liver failure</td>
		</tr>
		<tr>
			<td>Renal failure</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<table>
	<tbody>
		<tr>
			<td><strong>Adverse Effects</strong></td>
		</tr>
		<tr>
			<td>Most are dose-related and are unlikely with doses under 2mg/kg/hour</td>
		</tr>
		<tr>
			<td>
			<p>Cardiovascular</p>

			<ul>
				<li>Hypotension</li>
				<li>Bradycardia</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td>
			<p>Neuromuscular</p>

			<ul>
				<li>Light-headedness</li>
				<li>Tingling</li>
				<li>Muscle spasm</li>
				<li>Dysphasia</li>
				<li>Seizures</li>
				<li>Drowsiness</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td>Respiratory arrest</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<p>&#160;</p>


</body></html>